KR101751371B1 - Anticancer composition comprising 3,4,5-trihydroxybenzoic acid, its derivatives or its salts for preventing or treating receptor tyrosine kinase inhibitor resistant tumor - Google Patents
Anticancer composition comprising 3,4,5-trihydroxybenzoic acid, its derivatives or its salts for preventing or treating receptor tyrosine kinase inhibitor resistant tumor Download PDFInfo
- Publication number
- KR101751371B1 KR101751371B1 KR1020150090436A KR20150090436A KR101751371B1 KR 101751371 B1 KR101751371 B1 KR 101751371B1 KR 1020150090436 A KR1020150090436 A KR 1020150090436A KR 20150090436 A KR20150090436 A KR 20150090436A KR 101751371 B1 KR101751371 B1 KR 101751371B1
- Authority
- KR
- South Korea
- Prior art keywords
- cancer
- tyrosine kinase
- receptor tyrosine
- carcinoma
- acid
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 85
- 239000000203 mixture Substances 0.000 title claims abstract description 32
- 150000003839 salts Chemical class 0.000 title claims description 33
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 title abstract description 85
- 229940124617 receptor tyrosine kinase inhibitor Drugs 0.000 title abstract description 4
- 230000001093 anti-cancer Effects 0.000 title description 9
- 201000011510 cancer Diseases 0.000 claims abstract description 66
- 239000002246 antineoplastic agent Substances 0.000 claims abstract description 44
- 239000004480 active ingredient Substances 0.000 claims abstract description 31
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims abstract description 31
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims abstract description 29
- 229960002584 gefitinib Drugs 0.000 claims abstract description 29
- 229940041181 antineoplastic drug Drugs 0.000 claims abstract description 27
- 150000001875 compounds Chemical class 0.000 claims abstract description 24
- 108091008598 receptor tyrosine kinases Proteins 0.000 claims abstract description 20
- 102000027426 receptor tyrosine kinases Human genes 0.000 claims abstract description 19
- 102000009465 Growth Factor Receptors Human genes 0.000 claims description 25
- 108010009202 Growth Factor Receptors Proteins 0.000 claims description 25
- -1 trihydroxybenzoic acid compound Chemical class 0.000 claims description 25
- 230000008472 epithelial growth Effects 0.000 claims description 20
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 18
- 238000011282 treatment Methods 0.000 claims description 18
- 210000003169 central nervous system Anatomy 0.000 claims description 14
- 201000003914 endometrial carcinoma Diseases 0.000 claims description 14
- 208000016691 refractory malignant neoplasm Diseases 0.000 claims description 14
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 13
- 201000005202 lung cancer Diseases 0.000 claims description 13
- 208000020816 lung neoplasm Diseases 0.000 claims description 13
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims description 12
- 229960001433 erlotinib Drugs 0.000 claims description 12
- 239000000126 substance Substances 0.000 claims description 11
- 208000005431 Endometrioid Carcinoma Diseases 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 10
- 208000028730 endometrioid adenocarcinoma Diseases 0.000 claims description 10
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 10
- 230000002265 prevention Effects 0.000 claims description 10
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 9
- 239000004615 ingredient Substances 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 8
- 206010047741 Vulval cancer Diseases 0.000 claims description 8
- 229940079593 drug Drugs 0.000 claims description 8
- 201000000849 skin cancer Diseases 0.000 claims description 8
- 201000004916 vulva carcinoma Diseases 0.000 claims description 8
- 208000013013 vulvar carcinoma Diseases 0.000 claims description 8
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 7
- 206010046766 uterine cancer Diseases 0.000 claims description 7
- 206010006187 Breast cancer Diseases 0.000 claims description 6
- 208000026310 Breast neoplasm Diseases 0.000 claims description 6
- 206010014733 Endometrial cancer Diseases 0.000 claims description 6
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 6
- 208000007913 Pituitary Neoplasms Diseases 0.000 claims description 6
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 6
- 239000002671 adjuvant Substances 0.000 claims description 6
- 231100000135 cytotoxicity Toxicity 0.000 claims description 6
- 230000003013 cytotoxicity Effects 0.000 claims description 6
- 206010017758 gastric cancer Diseases 0.000 claims description 6
- 230000001939 inductive effect Effects 0.000 claims description 6
- 201000011549 stomach cancer Diseases 0.000 claims description 6
- 206010005003 Bladder cancer Diseases 0.000 claims description 5
- 206010009944 Colon cancer Diseases 0.000 claims description 5
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 5
- 230000006907 apoptotic process Effects 0.000 claims description 5
- 208000029742 colonic neoplasm Diseases 0.000 claims description 5
- 235000013402 health food Nutrition 0.000 claims description 5
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 5
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 5
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 5
- 206010005949 Bone cancer Diseases 0.000 claims description 4
- 208000018084 Bone neoplasm Diseases 0.000 claims description 4
- 206010006143 Brain stem glioma Diseases 0.000 claims description 4
- 201000009030 Carcinoma Diseases 0.000 claims description 4
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 4
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 claims description 4
- 208000017604 Hodgkin disease Diseases 0.000 claims description 4
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 4
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 4
- 201000005746 Pituitary adenoma Diseases 0.000 claims description 4
- 206010061538 Pituitary tumour benign Diseases 0.000 claims description 4
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 4
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims description 4
- 201000004101 esophageal cancer Diseases 0.000 claims description 4
- 201000002313 intestinal cancer Diseases 0.000 claims description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 4
- 201000001441 melanoma Diseases 0.000 claims description 4
- 201000002528 pancreatic cancer Diseases 0.000 claims description 4
- 208000021310 pituitary gland adenoma Diseases 0.000 claims description 4
- 206010062261 spinal cord neoplasm Diseases 0.000 claims description 4
- 231100000433 cytotoxic Toxicity 0.000 claims description 3
- 229940127089 cytotoxic agent Drugs 0.000 claims description 3
- 230000001472 cytotoxic effect Effects 0.000 claims description 3
- 230000001747 exhibiting effect Effects 0.000 claims description 2
- 229940127084 other anti-cancer agent Drugs 0.000 claims description 2
- 206010046458 Urethral neoplasms Diseases 0.000 claims 6
- 206010039491 Sarcoma Diseases 0.000 claims 4
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims 4
- 206010000830 Acute leukaemia Diseases 0.000 claims 2
- 208000001976 Endocrine Gland Neoplasms Diseases 0.000 claims 2
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 2
- 206010052178 Lymphocytic lymphoma Diseases 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 208000032271 Malignant tumor of penis Diseases 0.000 claims 2
- 208000002471 Penile Neoplasms Diseases 0.000 claims 2
- 206010034299 Penile cancer Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 2
- 208000035269 cancer or benign tumor Diseases 0.000 claims 2
- 208000024207 chronic leukemia Diseases 0.000 claims 2
- 201000010175 gallbladder cancer Diseases 0.000 claims 2
- 208000029559 malignant endocrine neoplasm Diseases 0.000 claims 2
- 201000002511 pituitary cancer Diseases 0.000 claims 2
- 201000002510 thyroid cancer Diseases 0.000 claims 2
- 239000013589 supplement Substances 0.000 claims 1
- 229940074391 gallic acid Drugs 0.000 abstract description 19
- 235000004515 gallic acid Nutrition 0.000 abstract description 19
- BRRSNXCXLSVPFC-UHFFFAOYSA-N 2,3,4-Trihydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C(O)=C1O BRRSNXCXLSVPFC-UHFFFAOYSA-N 0.000 abstract description 12
- 230000002147 killing effect Effects 0.000 abstract description 3
- 210000004027 cell Anatomy 0.000 description 58
- 238000002360 preparation method Methods 0.000 description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 238000004519 manufacturing process Methods 0.000 description 12
- 230000010261 cell growth Effects 0.000 description 11
- 230000012010 growth Effects 0.000 description 11
- 102000001301 EGF receptor Human genes 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 108060006698 EGF receptor Proteins 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 229940121647 egfr inhibitor Drugs 0.000 description 9
- 230000036541 health Effects 0.000 description 9
- WKOLLVMJNQIZCI-UHFFFAOYSA-N vanillic acid Chemical compound COC1=CC(C(O)=O)=CC=C1O WKOLLVMJNQIZCI-UHFFFAOYSA-N 0.000 description 9
- TUUBOHWZSQXCSW-UHFFFAOYSA-N vanillic acid Natural products COC1=CC(O)=CC(C(O)=O)=C1 TUUBOHWZSQXCSW-UHFFFAOYSA-N 0.000 description 9
- 230000035772 mutation Effects 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 235000013361 beverage Nutrition 0.000 description 7
- 239000002775 capsule Substances 0.000 description 7
- 235000013305 food Nutrition 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 6
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 230000003833 cell viability Effects 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 6
- 239000008187 granular material Substances 0.000 description 6
- 239000003112 inhibitor Substances 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 239000002502 liposome Substances 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 238000010293 colony formation assay Methods 0.000 description 5
- 210000002919 epithelial cell Anatomy 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 239000011859 microparticle Substances 0.000 description 5
- 239000004005 microsphere Substances 0.000 description 5
- YQUVCSBJEUQKSH-UHFFFAOYSA-N protochatechuic acid Natural products OC(=O)C1=CC=C(O)C(O)=C1 YQUVCSBJEUQKSH-UHFFFAOYSA-N 0.000 description 5
- 239000008213 purified water Substances 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 4
- 231100000002 MTT assay Toxicity 0.000 description 4
- 238000000134 MTT assay Methods 0.000 description 4
- 150000001720 carbohydrates Chemical class 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 4
- 229960002411 imatinib Drugs 0.000 description 4
- 238000011081 inoculation Methods 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 230000004614 tumor growth Effects 0.000 description 4
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000003560 cancer drug Substances 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 235000013376 functional food Nutrition 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 239000000017 hydrogel Substances 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 150000008442 polyphenolic compounds Chemical class 0.000 description 3
- 235000013824 polyphenols Nutrition 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 2
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 2
- 201000004384 Alopecia Diseases 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 2
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 2
- 206010007953 Central nervous system lymphoma Diseases 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 101710113436 GTPase KRas Proteins 0.000 description 2
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 102000043136 MAP kinase family Human genes 0.000 description 2
- 108091054455 MAP kinase family Proteins 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 239000005913 Maltodextrin Substances 0.000 description 2
- 229920002774 Maltodextrin Polymers 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 150000001340 alkali metals Chemical class 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 230000035578 autophosphorylation Effects 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 229960000397 bevacizumab Drugs 0.000 description 2
- 229920002988 biodegradable polymer Polymers 0.000 description 2
- 239000004621 biodegradable polymer Substances 0.000 description 2
- 229960004117 capecitabine Drugs 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 229940043241 conventional cytotoxic antineoplastic drug Drugs 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000007913 intrathecal administration Methods 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 229940041476 lactose 100 mg Drugs 0.000 description 2
- 229940035034 maltodextrin Drugs 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- CXKWCBBOMKCUKX-UHFFFAOYSA-M methylene blue Chemical compound [Cl-].C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 CXKWCBBOMKCUKX-UHFFFAOYSA-M 0.000 description 2
- 229960000907 methylthioninium chloride Drugs 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 229950008835 neratinib Drugs 0.000 description 2
- ZNHPZUKZSNBOSQ-BQYQJAHWSA-N neratinib Chemical compound C=12C=C(NC\C=C\CN(C)C)C(OCC)=CC2=NC=C(C#N)C=1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 ZNHPZUKZSNBOSQ-BQYQJAHWSA-N 0.000 description 2
- 235000012149 noodles Nutrition 0.000 description 2
- 238000011580 nude mouse model Methods 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 201000010198 papillary carcinoma Diseases 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000000419 plant extract Substances 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 208000016800 primary central nervous system lymphoma Diseases 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- GGCZERPQGJTIQP-UHFFFAOYSA-N sodium;9,10-dioxoanthracene-2-sulfonic acid Chemical compound [Na+].C1=CC=C2C(=O)C3=CC(S(=O)(=O)O)=CC=C3C(=O)C2=C1 GGCZERPQGJTIQP-UHFFFAOYSA-N 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 229960004964 temozolomide Drugs 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 2
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- XOMRRQXKHMYMOC-NRFANRHFSA-N (3s)-3-hexadecanoyloxy-4-(trimethylazaniumyl)butanoate Chemical compound CCCCCCCCCCCCCCCC(=O)O[C@@H](CC([O-])=O)C[N+](C)(C)C XOMRRQXKHMYMOC-NRFANRHFSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 1
- HNLXNOZHXNSSPN-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CC(C)(C)CC(C)(C)C1=CC=C(OCCOCCOCCOCCOCCOCCOCCO)C=C1 HNLXNOZHXNSSPN-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- BNNMDMGPZUOOOE-UHFFFAOYSA-N 4-methylbenzenesulfonic acid Chemical class CC1=CC=C(S(O)(=O)=O)C=C1.CC1=CC=C(S(O)(=O)=O)C=C1 BNNMDMGPZUOOOE-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 101100123850 Caenorhabditis elegans her-1 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 229940123011 Growth factor receptor antagonist Drugs 0.000 description 1
- 102100022623 Hepatocyte growth factor receptor Human genes 0.000 description 1
- 101710184069 Hepatocyte growth factor receptor Proteins 0.000 description 1
- 101000851181 Homo sapiens Epidermal growth factor receptor Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 229920002884 Laureth 4 Polymers 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- 229940121849 Mitotic inhibitor Drugs 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 102000016979 Other receptors Human genes 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 102000007568 Proto-Oncogene Proteins c-fos Human genes 0.000 description 1
- 108010071563 Proto-Oncogene Proteins c-fos Proteins 0.000 description 1
- 244000294611 Punica granatum Species 0.000 description 1
- 235000014360 Punica granatum Nutrition 0.000 description 1
- 101800001295 Putative ATP-dependent helicase Proteins 0.000 description 1
- 101800001006 Putative helicase Proteins 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 239000000877 Sex Attractant Substances 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 229940123237 Taxane Drugs 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- IAJILQKETJEXLJ-RSJOWCBRSA-N aldehydo-D-galacturonic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-RSJOWCBRSA-N 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 125000005233 alkylalcohol group Chemical group 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 239000003080 antimitotic agent Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 229960005261 aspartic acid Drugs 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 229940093761 bile salts Drugs 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229940037769 calcium carbonate 100 mg Drugs 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000009087 cell motility Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 229940069647 citric acid 1000 mg Drugs 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 150000001896 cresols Chemical class 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 235000001497 healthy food Nutrition 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 229940084651 iressa Drugs 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 229940062711 laureth-9 Drugs 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- AHLKSOXEVRYIRD-UHFFFAOYSA-N n-phenylquinazolin-2-amine Chemical compound N=1C=C2C=CC=CC2=NC=1NC1=CC=CC=C1 AHLKSOXEVRYIRD-UHFFFAOYSA-N 0.000 description 1
- 230000007694 nephrotoxicity Effects 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 229940098514 octoxynol-9 Drugs 0.000 description 1
- 229920002114 octoxynol-9 Polymers 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- WVUNYSQLFKLYNI-AATRIKPKSA-N pelitinib Chemical compound C=12C=C(NC(=O)\C=C\CN(C)C)C(OCC)=CC2=NC=C(C#N)C=1NC1=CC=C(F)C(Cl)=C1 WVUNYSQLFKLYNI-AATRIKPKSA-N 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- ONJQDTZCDSESIW-UHFFFAOYSA-N polidocanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO ONJQDTZCDSESIW-UHFFFAOYSA-N 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229960003975 potassium Drugs 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 150000004944 pyrrolopyrimidines Chemical class 0.000 description 1
- 150000003246 quinazolines Chemical class 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 229960000342 retinol acetate Drugs 0.000 description 1
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 1
- 235000019173 retinyl acetate Nutrition 0.000 description 1
- 239000011770 retinyl acetate Substances 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 229910001961 silver nitrate Inorganic materials 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 description 1
- OABYVIYXWMZFFJ-ZUHYDKSRSA-M sodium glycocholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 OABYVIYXWMZFFJ-ZUHYDKSRSA-M 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- JAJWGJBVLPIOOH-IZYKLYLVSA-M sodium taurocholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 JAJWGJBVLPIOOH-IZYKLYLVSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229940120982 tarceva Drugs 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical group C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229960003087 tioguanine Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- RMNIZOOYFMNEJJ-UHFFFAOYSA-K tripotassium;phosphate;hydrate Chemical compound O.[K+].[K+].[K+].[O-]P([O-])([O-])=O RMNIZOOYFMNEJJ-UHFFFAOYSA-K 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 229940033203 vitamin b6 0.5 mg Drugs 0.000 description 1
- 238000002689 xenotransplantation Methods 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/308—Foods, ingredients or supplements having a functional effect on health having an effect on cancer prevention
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
Abstract
The present invention relates to a trihydroxybenzoic acid (gallic acid) compound or a derivative thereof, which specifically inhibits a cancer cell that is resistant to an anticancer agent that targets a receptor tyrosine kinase The present invention relates to a composition for preventing or treating a cancerous cancer against a target anticancer agent comprising an active ingredient, wherein the trihydroxybenzoic acid (gallic acid) compound or a derivative thereof is a receptor tyrosine kinase kinase of the present invention can be prevented or treated by a receptor tyrosine kinase inhibitor such as gefitinib by specifically killing cancer cells that are resistant to an anticancer drug that targets cancer cells.
Description
The present invention relates to a trihydroxybenzoic acid (gallic acid) compound or a derivative thereof, which specifically inhibits a cancer cell that is resistant to an anticancer agent that targets a receptor tyrosine kinase And a composition for preventing or treating resistant cancer diseases against a target anticancer agent which is contained as an active ingredient.
According to a recent report by the Central Cancer Registry, cancer incidence in Korea has increased by 3.5% every year for the past 10 years. In 2010, more than 200,000 people were newly diagnosed with cancer. In Korea, the odds of getting cancer are almost two out of five, and women up to 84 years old have only one in three. Cancer is becoming increasingly common disease. The number of new cancer patients in the world was 12.7 million in 2008, 5.6 million in developed countries and 7.1 million in developing countries. By 2030, there will be 21.4 million new cancer cases and death toll of 13.2 million cancer cases. As the incidence of cancer continues to increase not only in Korea but also in the world, the importance of developing effective cancer drugs is also increasing. The global market for anticancer drugs will exceed 70 trillion won by 2010, reaching 84 trillion won by 2013. This sustained growth in market size supports the fact that research for the development of anticancer drugs is actively being carried out globally.
Conventional anticancer drugs have been used to block the cell cycle of each stage, which can induce cytotoxicity. However, this toxicity has caused side effects such as nausea, vomiting and hair loss while attacking normal cells. However, recently, in order to overcome the side effects of these conventional cytotoxic anticancer drugs, research on target anticancer drugs targeting only cancer cells has become popular. The target anticancer agent is noticed that the cancer cells are generated by the gene mutation process of the normal cells, and the agent that reacts with the mutation of the cell is targeted, and the substance that reacts with the target is administered to block the change of cancer cells . Targeted anticancer drugs have little effect on normal cells, so they are attracting attention as a next-generation anticancer drug with relatively low side effects. Therefore, investments and research are being conducted competitively to preempt the target cancer drug market worldwide.
Recently, the tyrosine kinase inhibitor (EGFR-TKIs) of the epithelial cell growth factor receptor has been attracting attention as a novel therapeutic agent for non-small cell lung cancer as a molecular target therapeutic agent (Shepherd FA et al (1994) Semin Oncol 21: 7-18).
Epidermal growth factor receptor (EGFR) is the first known receptor tyrosine kinase receptor tyrosine kinase, a membrane binding protein of 170 kilodaltons (kDa) expressed on the surface of epithelial cells. Epithelial cell growth factor receptors are members of the growth factor receptor family of the protein tyrosine kinases, the cell cycle regulatory molecule class (W. J. Gullick et al., 1986, Cancer Res., 46: 285-292). The epithelial growth factor receptor is activated when its ligand epithelial cell growth factor (EGF) binds to the extracellular domain, thereby causing autophosphorylation of the intracellular tyrosine kinase domain of the receptor (S. Cohen et al., 1980 , J. Biol. Chem., 255: 4834-4842; AB Schreiber et al., 1983, J. Biol. Chem., 258: 846-853) signal transduction pathway is activated and cell proliferation occurs as a result.
The epithelial growth factor receptor is a protein product of erbB or ErbB1, a growth-promoting oncogene, which is a member of the ERBB family of primary oncogenes and is believed to play a pivotal role in the pathogenesis and progression of many human cancers. Indeed, the expression of the receptor is continuously observed in overexpressed or mutant forms of epithelial growth factor receptor in breast cancer, bladder cancer, lung cancer, head cancer, cervical cancer, gastric cancer as well as glioblastoma.
Cancer occurs because cell proliferation is not regulated as a result of genetic mutations affecting the function of growth factor receptor function or inducing overexpression of the receptor and / or ligand.
In particular, the epithelial growth factor receptor has been shown to play an important role in the resistance of cancer cells to cell differentiation, cell motility enhancement, protein secretion, angiogenesis, invasion, metastasis, chemotherapeutic agents and radiation (MJ Oh et al , 2000, Clin. Cancer Res., 6: 4760-4763).
In addition to the hypothesis that suppression of epithelial growth factor receptor may be a target of new chemotherapy, monoclonal antibodies that inhibit receptor binding of the ligand by its therapeutic method and small molecules inhibiting autophosphorylation of tyrosine kinase of intracellular domain (Kawamoto et al (1983) Proc. Natl. Acad Sci. USA 80: 1337-1341).
Thus, epithelial growth factor receptors have been the target of choice for the development of several different cancer therapies. EGFR tyrosine kinase inhibitors (EGFR-TKIs) are one of these therapies because activation of the epithelial growth factor receptor pathway requires reversible phosphorylation of tyrosine residues. In other words, epithelial growth factor receptor tyrosine kinase inhibitors (EGFR-TKI) block the activity of cell surface receptors that are responsible for triggering and / or maintaining signaling pathways in cells that cause growth and differentiation of tumor cells. Specifically, these inhibitors block the activity of the receptor by blocking the adenosine triphosphate (ATP) binding domain of the epithelial cell growth factor receptor kinase, termed HER-1, so that the ATP does not bind any more . The epithelial growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) is known as the quinazolines pyridopyrimidines, and pyrrolopyrimidines compounds.
Recently, a variety of inhibitors against epithelial growth factor receptor have been identified and two new quinazolines compounds approved after clinical development have been identified, including Gefitinib (compound ZD1839 developed by AstraZeneca UK Ltd.; (Available under the trade name IRESSA) and Erlotinib (the compound OSI774 developed by Genentech, Inc. and OSIPharmaceuticals, Inc., available under the trade name TARCEVA), both of which exhibited encouraging clinical results Presentations at ASCO 2003 and WCLC, Aug.2003).
In particular, Gefitinib is the first commercially available orally administered epithelial growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) and has been shown to inhibit the growth of various solid tumors such as lung, colon, and breast cancer in preclinical studies William Pao et al (2005) J Clin Oncol 23: 2556-2568; Herbst R et al (2004) Nat Rev Cancer 4: 956-65; Miller VA et al (2004) J Clin Oncol 22: 1103-1109). Gefinitib is a small synthetic anilinoquinazoline that has minimal inhibitory activity on other tyrosine kinases (TKs) and selectively activates the epithelial growth factor receptor tyrosine kinase (EGFR-TK) . It also inhibits mitogen-activated protein kinase (MAPK) and inhibits the subsequent nuclear transcription factor c-fos. Basically, this drug inhibits growth but induces apoptosis at high doses. Gefitinib has not only improved the toxicity and side effects of conventional cytotoxic anticancer drugs such as bone marrow suppression, nephrotoxicity, nausea, vomiting and alopecia but also oral treatment.
However, the epithelial growth factor receptor (EGFR) target inhibitor, gefitinib, has been implicated in the development of drug resistance due to the expression of the epithelial growth factor receptor (EGFR) T790M or the protooncogene c-Met Respectively. In fact, it has been shown that zetytipine has a remarkable therapeutic effect with a response rate of about 15% in patients. However, when taken for about 1 year, it is important to make a plan to overcome the cancer, It is emerging as a task.
Trihydroxybenzoic acid, also called gallic acid or gallate, is found in various plant extracts. (1999) Anticancer Drugs 10 (9): 845-51; Ho et al. (1999) have shown that gallic acid inhibits the growth of cancer cells such as lung cancer, stomach cancer and uterine cancer and induces apoptosis. (2010) Food and Chemical Toxicology 48 (8-9): 4834-4842; Zhao et al. (2013) Onco Letters 6: 1749-1755).
However, the anticancer effect that specifically kills cancer cells that are resistant to epithelial growth factor receptor inhibitors such as zetitifib and / or erlotinib has not been disclosed.
U.S. Patent No. 8,334,000 discloses that gallic acid and various derivatives of gallic acid contained in extracts of other plants including pomegranate inhibit the growth of malignant tumors by inhibiting angiogenesis, There is no mention of the therapeutic effect on cancers resistant to tyrosine kinase inhibitors at all.
Korean Patent Laid-Open Publication No. 2014-0015798 discloses a daphnane diterpenoid-based substance as an anticancer drug that kills cancer cells that are resistant to the Gefitinib anticancer drug. However, It is believed that a long validation period will be required until it is actually used as a resistance agent for the currently marketed zetotinib, since it kills not only cancer cells but also cancer cells which do not show resistance.
Korean Patent Publication No. 2007-0107693 (International Publication No. WO 2006/084058) discloses the use of EKB-569, HKI-272 or HKI-272 as an irreversible epithelial growth factor receptor antagonist against sextetin in zetitib or erlotinib, 357. However, this is based on the second mutation T790M occurring in the kinase domain among endometrial cancer cases, and the second mutation does not occur in all endometrial cancer, and since the compound is not a naturally occurring component, it is relatively toxic Therefore, a long verification time will be required until it is actually used as a resistance agent of zeta-nip.
Therefore, it selectively acts on cancer cells that are resistant to epithelial growth factor receptor inhibitors such as zetitib and / or erlotinib, which are currently on the market, to selectively kill resistant cancerous cells, A naturally occurring compound that can maximize the effect and minimize side effects is required.
It is an object of the present invention to provide a composition capable of inducing intracellular toxicity or apoptosis of cancer cells showing tolerance to an anticancer drug targeting receptor tyrosine kinase.
In order to achieve the above object, the present invention provides a pharmaceutical composition for preventing or ameliorating tolerable cancer diseases against a target anticancer drug comprising 3,4H-trihydroxybenzoic acid compound, a derivative thereof or a pharmaceutically acceptable salt thereof as an active ingredient. A composition for treating or preventing cancer, a functional anticancer agent, a functional health food capable of preventing or ameliorating cancer disease, a food which can prevent and improve cancer, including the effective ingredient, and an anticancer agent, To provide a combination that is capable of preventing or treating a target cancer-resistant cancer disease.
The composition according to the present invention specifically inhibits the receptor tyrosine kinase (receptor tyrosine kinase) -receptor-resistant cancer diseases such as gefitinib by specifically killing cancer cells that are resistant to an anticancer drug targeting receptor tyrosine kinase Can be prevented or treated.
Figure 1 shows the changes in cell growth of HCC827 cell line and resistant HCC827GR (gefitinib resistnace) cell line without resistance to gefitinib following treatment with different concentration of gefitinib by MTT assay As shown in FIG.
FIG. 2A shows the cell growth of HCC827 cell line and resistant HCC827GR (Gefitinib Resistnace) cell line which are not resistant to gefitinib following treatment with 3,4hydroxybenzoic acid (gallic acid), 3,4,5-trihydroxybenzoic acid (MTT) analysis of the change.
FIG. 2b is a graph showing the results of the reaction of 3,4-trihydroxybenzoic acid, gallic acid, gefitinib, 4-hydroxy-3-methoxybenzoic acid, vanillic acid ) And the colony formation assay of HCC827 cells and resistant HCC827GR (Gefitinib Resistnace) cells without resistance to gefitinib following treatment of each vehicle (Vehicle, Veh) .
Figure 3a shows the sensitivity of the cell lines of H358, H1650, H1666, H1734, H1975, HCC827, and H3255 to the expression of gefitinib and 3,4hydroxylbenzoic acid (gallic acid) (MTT) analysis method.
Figure 3b is a graph showing the effect of each treatment of 3,4,8-trihydroxybenzoic acid (gallic acid), gefitinib, and vehicle (Veh) on gefitinib The results of the colony formation assay of the resistant H358 and H1975 cell lines are shown.
Figs. 4A and 4B are graphs and photographs showing the results of a mouse experiment, showing a decrease in tumor volume. Fig.
The present invention relates to a method for the prevention of cancer-resistant diseases against target anticancer drugs comprising 3,4-trihydroxybenzoic acid compound represented by the following formula (1), a derivative thereof or a pharmaceutically acceptable salt thereof as an active ingredient Or therapeutic compositions.
[Chemical Formula 1]
.
The present invention relates to a pharmaceutical composition comprising a trihydroxybenzoic acid compound represented by the following
[Chemical Formula 1]
.
In one embodiment according to the present invention, the compound, its derivative or a pharmaceutically acceptable salt thereof may exhibit cytotoxicity in a cancer cell having resistance to a receptor tyrosine kinase target anticancer drug.
In one embodiment according to the present invention, the compound, its derivative or pharmaceutically acceptable salt thereof may exhibit cytotoxicity in a cancer cell which is resistant to an epithelial growth factor receptor (EGFR) target anticancer drug.
In one embodiment according to the present invention, the compound, a derivative thereof or a pharmaceutically acceptable salt thereof may exhibit a higher cytotoxic inducing effect in a drug-resistant cancer cell than in a normal cancer cell.
In one embodiment according to the present invention the targeted anticancer agent is selected from the group consisting of Gefitinib, temozolomide, bevacizumab, erlotinib, capecitabine and imatinib imatinib), but the present invention is not limited thereto.
In one embodiment according to the present invention the cancer disease is selected from the group consisting of breast cancer, lung cancer, non-small cell lung cancer, gastric cancer, colon cancer, bone cancer, pancreatic cancer, skin cancer, head cancer, head cancer, skin cancer, malignant melanoma, uterine cancer, Endometrioid carcinoma, endometrioid carcinoma, vulvar carcinoma, vulvar carcinoma, Hodgkin's disease, esophageal cancer, small bowel cancer, lymphadenocarcinoma, bladder cancer, endometrioid carcinoma, endometrioid carcinoma, Neoplasms, renal cell carcinomas, renal pelvic carcinomas, central nervous system (CNS) neoplasms, papillary carcinomas, pancreatic carcinomas, pancreatic carcinomas, pancreatic carcinomas, central nervous system (GI) tumors, primary central nervous system lymphoma, spinal cord tumors, brainstem glioma, and pituitary adenoma.
In one embodiment according to the present invention, the composition may be used alone or in combination with other anticancer agents.
In one embodiment according to the present invention, the compounds of the present invention or derivatives thereof may be prepared as pharmaceutically acceptable salts and solvates according to methods conventional in the art.
In one embodiment according to the present invention, as the salt, an acid addition salt formed by a pharmaceutically acceptable free acid is useful. Acid addition salts may be prepared in a conventional manner, for example, by dissolving the compound in an excess of an acid aqueous solution and precipitating the salt using a water-miscible organic solvent such as methanol, ethanol, acetone or acetonitrile, The acid or alcohol (e.g., glycol monomethyl ether) in water may be heated and then the mixture may be evaporated to dryness, or the precipitated salt may be filtered by suction.
In one embodiment, the free acid may be an organic acid or an inorganic acid. Examples of the inorganic acid include hydrochloric acid, phosphoric acid, sulfuric acid, nitric acid, tartaric acid and the like. Examples of the organic acid include methanesulfonic acid, p-toluenesulfonic acid, But are not limited to, acetic, trifluoroacetic, citric, maleic, succinic, oxalic, benzoic, tartaric, fumaric, mandelic, propionic, citric, glycollic acid, gluconic acid, galacturonic acid, glutamic acid, glutaric acid, glucuronic acid, aspartic acid, ascorbic acid, carbonic acid, vanillic acid, But is not limited thereto.
In one embodiment according to the invention, the base can be used to make a pharmaceutically acceptable metal salt. The alkali metal or alkaline earth metal salt is obtained, for example, by dissolving the compound in an excess amount of an alkali metal hydroxide or alkaline earth metal hydroxide solution, filtering the insoluble compound salt, and evaporating and drying the filtrate. At this time, it is preferable to produce sodium, potassium or calcium salt particularly as a metal salt, and the corresponding silver salt can be obtained by reacting an alkali metal or alkaline earth metal salt with a suitable silver salt (for example, silver nitrate).
In one embodiment according to the present invention, the pharmaceutically acceptable salts of the compounds of the invention or derivatives thereof may, unless otherwise indicated, include salts of acidic or basic groups which may be present in the compounds, Pharmaceutically acceptable salts include the sodium, calcium and potassium salts of the hydroxy group and the other pharmaceutically acceptable salts of the amino group include hydrobromide, sulfate, hydrogen sulfate, phosphate, hydrogen phosphate, dihydrogen phosphate, acetate, (Mesylate) and p-toluenesulfonate (tosylate) salts, which may be prepared by methods or processes known to those skilled in the art, such as, for example, .
The present invention relates to a pharmaceutical composition for prevention or treatment of cancer-resistant cancer, which comprises as an
[Chemical Formula 1]
.
In one embodiment of the present invention, the compound, its derivative or a pharmaceutically acceptable salt thereof may exhibit cytotoxicity in a cancer cell having resistance to a receptor tyrosine kinase target anticancer drug.
In one embodiment according to the present invention, the compound, its derivative or a pharmaceutically acceptable salt thereof may exhibit cytotoxicity in a cancer cell which is resistant to the epithelial growth factor receptor (EGFR) target anticancer drug.
In one embodiment according to the present invention, the compound, a derivative thereof or a pharmaceutically acceptable salt thereof may exhibit a higher cytotoxic inducing effect in a drug-resistant cancer cell than in a normal cancer cell.
In one embodiment according to the present invention the targeted anticancer agent is selected from the group consisting of Gefitinib, temozolomide, bevacizumab, erlotinib, capecitabine and imatinib imatinib), but the present invention is not limited thereto.
In one embodiment according to the present invention the cancer disease is selected from the group consisting of breast cancer, lung cancer, non-small cell lung cancer, gastric cancer, colon cancer, bone cancer, pancreatic cancer, skin cancer, head cancer, head cancer, skin cancer, malignant melanoma, uterine cancer, Endometrioid carcinoma, endometrioid carcinoma, vulvar carcinoma, vulvar carcinoma, Hodgkin's disease, esophageal cancer, small bowel cancer, lymphadenocarcinoma, bladder cancer, endometrioid carcinoma, endometrioid carcinoma, Neoplasms, renal cell carcinomas, renal pelvic carcinomas, central nervous system (CNS) neoplasms, papillary carcinomas, pancreatic carcinomas, pancreatic carcinomas, pancreatic carcinomas, central nervous system (GI) tumors, primary central nervous system lymphoma, spinal cord tumors, brainstem glioma, and pituitary adenoma.
In one embodiment of the present invention, the anticancer adjuvant of the present invention may further contain one or more active ingredients exhibiting the same or similar functions, and the pharmaceutically acceptable carrier may be saline, sterilized water, Ringer's solution, buffer Saline solution, dextrose solution, maltodextrin solution, glycerol, ethanol, and at least one of these components may be used in combination.
The present invention relates to a pharmaceutical composition for prevention of cancer-resistant cancer diseases, which comprises as an
[Chemical Formula 1]
.
In one embodiment of the present invention, the anticancer agent includes antimetabolites such as methotrexate, 6-mercaptopurine, 6-thioguanine, 5-fluorouracil and cytarabine; An alkylating agent such as a chlorambucil, a cyclophosphamide, an ethylene imine compound, an alkyl sulfonate compound, a carnustine compound or a dacarbazine compound, ); Antitumor agents such as actinomycin D, doxorubicin, bleomycin and mitomycin, plant alkaloids such as vincristine and vinblastine, and mitotic inhibitors such as taxoid, a mitotic inhibitor containing a taxane ring antimitotic drugs); Hormones such as corticosteroids or progesterone; Platinum-containing compounds such as cisplatin, but are not limited thereto.
The present invention includes the step of administering an effective amount of said composition, anticancer adjuvant, or combination thereof to a patient in need of gametin treatment of zetitib or erlotinib.
In one embodiment according to the present invention, the treatment may include treatment with other receptor tyrosine kinases such as zetitib or erlotinib, chemotherapy, radiation therapy, and the like, It is not.
In one embodiment according to the present invention, an effective amount of said composition, anticancer adjuvant, or combination thereof may be administered to a mammal, including a human, by a variety of routes.
In one embodiment according to the present invention, the effective amount may vary depending on the age, weight, sex, health condition, drug form, dosage form, disease severity, tumor mass, A statistically significant fraction can be determined taking into account the amount that yields a beneficial effect.
In one embodiment according to the present invention, the effective dose will generally be from 0.001 mg / kg to 10 g / kg per day, more preferably from 0.01 mg / kg to 1 g / kg per day, And may be administered in divided doses as needed, but the dose is not intended to limit the scope of the invention in any way.
In one embodiment according to the present invention, in addition to the active ingredient of the present invention, one or more further pharmaceutically acceptable carriers may be prepared.
In one embodiment according to the present invention, the pharmaceutically acceptable carrier is selected from the group consisting of saline, sterile water, Ringer's solution, buffered saline, dextrose solution, maltodextrin solution, glycerol, ethanol, liposome, And other conventional additives such as an antioxidant, a buffer, and a bacteriostatic agent may be added as needed. In addition, it can be formulated into injection formulations, pills, capsules, granules or tablets such as aqueous solutions, suspensions, emulsions and the like by additionally adding diluents, dispersants, surfactants, binders and lubricants, Specific antibody or other ligand can be used in combination with the carrier. Can further be suitably formulated according to the respective disease or ingredient, using appropriate methods in the art or as disclosed in Remington's Pharmaceutical Science (recent edition), Mack Publishing Company, Easton PA have.
In one embodiment according to the present invention, the formulations may be prepared using, but not limited to, diluents or excipients such as commonly used fillers, extenders, binders, wetting agents, disintegrants, surfactants and the like.
In one embodiment according to the present invention, the dosage form is not particularly limited, but may be administered parenterally or orally, as desired.
In one embodiment according to the present invention said parenteral administration is intravenous (iv), intramuscular (im), subcutaneous (sc), intradermal (id), intraperitoneal (ip), intrathecal (it) Intramuscular, intrathecal, intrauterine, rectal, vaginal, topical, intratumoral, and the like, and may be administered parenterally by injection or by gradual infusion over time and delivered by peristaltic means.
In one embodiment of the present invention, the preparation for parenteral administration includes a sterilized aqueous solution, a non-aqueous solvent, a suspension, an emulsion, a freeze-dried preparation, a suppository, and the like. Examples of the non-aqueous solvent and suspending agent include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like. As a base for suppositories, witepsol, macrogol, tween 61, cacao paper, laurin, glycerol, gelatin and the like can be used.
In one embodiment according to the present invention, the solid dosage forms for oral administration include tablets, pills, powders, granules, capsules, troches and the like, which may contain one or more excipients For example, it is prepared by mixing starch, calcium carbonate, sucrose, lactose or gelatin. In addition to simple excipients, lubricants such as magnesium stearate talc are also used. Examples of the liquid preparation for oral administration include suspensions, solutions, emulsions or syrups. In addition to water and liquid paraffin which are commonly used simple diluents, various excipients such as wetting agents, sweeteners, fragrances, preservatives and the like have.
In one embodiment according to the present invention, the agent for oral administration may be provided together with an enhancer. Orally acceptable absorption enhancers include surfactants such as sodium lauryl sulfate, palmitoyl carnitine, laureth-9, phosphatidylcholine, cyclodextrin and their derivatives; Bile salts such as sodium deoxycholate, sodium taurocholate, sodium glycocholate, and sodium pushidate; Chelating agents such as EDTA, citric acid and salicylate; And fatty acids (e.g., oleic acid, lauric acid, acylcarnitines, mono and diglycerides). Other oral absorption enhancers include benzalkonium chloride, benzethonium chloride, CHAPS (3- (3-cholamidopropyl) -dimethylammonio-1-propanesulfonate), Big-CHAPS (N, 3-D-glucoamidopropyl) -colamide), chlorobutanol, octoxynol-9, benzyl alcohol, phenols, cresols, and alkyl alcohols.
In one embodiment according to the present invention, the active ingredient of the present invention may be administered in liposomes or microspheres (or microparticles).
In one embodiment according to the present invention, the active ingredient of the present invention can be implanted into a complex of microspheres or microspheres and transplanted to be slowly released over a period of several days to several months.
In one embodiment according to the present invention, the microspheres are formed from polymers or proteins and are known to those skilled in the art and can be tailored to pass through the gastrointestinal tract directly into the bloodstream.
In one embodiment according to the present invention, the active ingredient of the present invention may be formulated into the liposomes or microparticles (microspheres) and administered intravenously in a size suitable to lodge capillary blood vessels.
In one embodiment according to the present invention, when the liposomes or microparticles reach capillary blood vessels around the ischemic tissue, the active ingredients may be administered topically to the site where they may be most effective.
In one embodiment according to the present invention, the liposome is generally less than about 200 nm and may be a multilayer vesicle to target ischemic tissue.
In one embodiment according to the present invention, the microparticles may be those made from biodegradable polymers such as polyglycolide, polylactide and copolymers thereof, and those skilled in the art will appreciate that the desired drug release rate and the desired dosage A suitable carrier system can be easily determined according to various factors such as the amount of the carrier.
In one embodiment according to the present invention, the formulation containing the active ingredient of the present invention may be administered directly into a blood vessel through a catheter, wherein the active ingredient may be contained in the biodegradable polymer hydrogel.
In one embodiment according to the present invention, the polymer hydrogel may be delivered into a tissue lumen, and a formulation containing the active ingredient of the present invention may be released over time as the polymer degrades.
In one embodiment according to the present invention, the polymeric hydrogel may have microparticles or liposomes in which the active ingredient of the present invention is dispersed, which provides another mechanism for controlled release of the active ingredient of the present invention .
In one embodiment according to the present invention, the agent comprising the active ingredient of the present invention for such administration may be prepared by a method known in the pharmaceutical field and suitably provided in unit dosage form, Contacting the component with a carrier that constitutes one or more accessory ingredients.
In one embodiment according to the present invention, the preparation is prepared by uniformly and densely contacting the active ingredient of the present invention with a liquid carrier or a finely divided solid carrier, and then, if necessary, shaping the product into the desired unit dosage form ).
In one embodiment according to the present invention, the formulation comprising the active ingredient may contain one or more optional auxiliary ingredients such as diluents, buffers, spices, binders, surface active agents, thickeners, lubricants, suspensions A preservative (antioxidant, etc.), and the like.
In one embodiment according to the present invention, the active ingredient of the present invention may be administered alone or in combination with an inert carrier such as lactose, for administration to the respiratory tract, as a solution for snuff or an aerosol or inhaler or as an ultra- In which case the particles of the active ingredient are suitable to have a diameter of less than 50 microns, preferably less than 10 microns, more preferably 2 to 5 microns.
In one embodiment according to the present invention, the composition for nasal administration is desirably weakly acidic in pH, and more specifically the pH is preferably from about 3 to about 5, more specifically from about 3.5 to about 3.9, Hydrochloric acid, and the like.
The present invention relates to a pharmaceutical composition for preventing or ameliorating a cancer-resistant cancer drug, which comprises a 3,4-trihydroxybenzoic acid compound represented by the following formula (1), a derivative thereof or a pharmaceutically acceptable salt thereof as an active ingredient Health functional foods.
[Chemical Formula 1]
.
The health functional food may be variously used for medicines, foods, beverages and the like, and can be commercialized in the form of tablets, capsules, pills, powders, granules, liquid beverages, concentrates and the like.
In the case of health functional foods in the form of granules, tablets or capsules, it is generally 0.0001 to less than 100% by weight, more particularly 0.01 to 80% by weight, more particularly 0.1 to 50% by weight, more particularly 1 to 20% The active ingredient of the present invention may be added, but not limited thereto.
The present invention relates to a food for preventing and / or improving cancer, which comprises as an
[Chemical Formula 1]
.
Such foods include beverages, meats, chocolates, confectionery, pizza. Examples of the foodstuffs include noodles, noodles, gums, ice creams, vitamin complexes, alcoholic beverages, dairy products, juices, rings, granules, teabags and sticks.
Generally, the food composition of the present invention may be added in an amount of 0.01 to 15% by weight of the total food, and the health beverage composition may be added in a proportion of 0.02 to 10 g, preferably 0.3 to 1 g, based on 100 ml.
In one embodiment according to the present invention, the health beverage composition of the present invention is not limited to liquid ingredients other than containing the active ingredient mixture of the present invention as an essential ingredient in the indicated ratios, and includes various flavors Or natural carbohydrate as an additional ingredient. Examples of such natural carbohydrates include conventional saccharides such as monosaccharides such as disaccharides such as glucose and fructose such as maltose and sucrose and polysaccharides such as dextrin and cyclodextrin and xylitol such as sorbitol , Erythritol, and the like. As a flavor other than the above, a natural flavoring agent (tau Martin, a stevia compound (e.g., rebaudioside A, glycyrrhizin, etc.) and synthetic flavorings (e.g., saccharin, aspartame etc.) The ratio of the natural carbohydrate is generally about 1 to 20 g, more specifically about 5 to 12 g per 100 ml of the beverage composition of the present invention.
Hereinafter, the present invention will be described in more detail with reference to the following Examples, Experimental Examples and Preparation Examples. It should be understood, however, that the same is by way of illustration and example only and is not intended to limit the scope of the present invention.
[Experimental Example]
<3,4,5-Trihydroxybenzoic acid compound>
The 3,4, 5-trihydroxybenzoic acid compound used in the experimental examples was purchased from Sigma-Aldrich and Alfa Aesar.
Experimental Example 1: Gefitinib-resistant cell line
Experimental Example 2 Cell Growth Response to 3,4 Hydroxybenzoic Acid of HCC827 Cell Lines
As a result, as shown in FIG. 2B, in the colony formation assay, cell growth inhibition and clonogenicity due to treatment with 3,4,5-trihydroxybenzoic acid were found to be dependent on the degree of resistance to zetti nip I could confirm the proportion. Furthermore, in the case of 4-hydroxy-3-methoxybenzoic acid, which is a similar polyphenol, no anticancer effect was observed. These results indicate that the antitumor effect of 3,4,5-trihydroxybenzoic acid is more specific to the sex pheromone of polyphenols than other polyphenols.
Experimental Example 3: Trihydroxybenzoic acid anti-cancer effect test from various lung cancer cell lines
Table 2 below shows IC 50 values for gefitinib in various lung cancer cell line panels with K-ras mutation and epithelial growth factor receptor (EGFR) mutation characteristics. (Table 2: Lt; RTI ID = 0.0 > IC50 < / RTI > values for gefitinib)
As a result, as shown in FIG. 3A, treatment of various lung cancer cell lines with 3,4,5-trihydroxybenzoic acid (gallic acid) resulted in a decrease in the sensitivities of japitinib and 3,4,5-trihydroxybenzoic acid As a result, the sensitivities of zetipine and 3,4,5-trihydroxybenzoic acid were found to be inversely proportional to almost all different lung cancer cell lines.
In addition, in order to measure the growth reaction of 3,4,5-trihydroxybenzoic acid in two cell lines having different mutations, but commonly having resistance to zetti nip, H358 having K-ras mutation and epithelium H1975 cell lines harboring mutants of the cell growth factor receptor (EGFR) were each inoculated into 6-well plates, and after 24 hours of inoculation, 0.3 uM zetitibim, 25
As a result, clonogenicity was disappeared by treatment with 3,4,5-trihydroxybenzoic acid in both H358 and H1975 cell lines, as shown in Fig. 3B. Therefore, it was confirmed that 3,4,5-trihydroxybenzoic acid had a specific anticancer effect if it had a zetti-nip resistance even in a mutant lung cancer cell line.
Experimental Example 4. Animal Experiment (tumor growth inhibitory effect)
A xenotransplantation experiment was conducted to determine the inhibitory effect of 3,4,5-trihydroxybenzoic acid on tumor growth. The experimental method is as follows:
5 × 10 6 H1650 lung cancer cells were subcutaneously injected into the side of nude mice. H1650-transplanted nude mice were randomly divided into two groups, four as control and six as experimental groups. DMSO was intraperitoneally administered to the control mice for 32 days from the time when the tumor volume reached 20 mm 3 , and the dose of 200 mg / kg of 3,4,5-trihydroxybenzoic acid was administered to the experimental mice every 2 days. The tumor volume was calculated as (x width x length x height).
Experimental results showed that the experimental group treated with 3,4,5-trihydroxybenzoic acid significantly inhibited tumor growth compared with the control group treated with DMSO. 4A is a graph showing the tumor growth inhibitory effect of H1650 transplanted mice. (p = 0.0211) It can be seen that when the 3,4,5-trihydroxybenzoic acid according to the present invention is administered, the tumor size is significantly reduced.
[Manufacturing Example]
Production Example 1. Preparation of powder
Trihydroxybenzoic acid (gallic acid) 200 mg
Lactose ------------------------------------------------- - 100 mg
Talc ------------------------------------------------- - 10 mg
The above components are mixed and filled in airtight bags to prepare powders.
Production Example 2. Preparation of tablets
Trihydroxybenzoic acid (gallic acid) 200 mg
Corn starch --------------------------------------------- 100 mg
Lactose ------------------------------------------------- - 100 mg
Magnesium stearate ------------------------------------ 2 mg
After mixing the above components, tablets are prepared by tableting according to the usual preparation method of tablets.
Preparation Example 3. Preparation of capsules
Trihydroxybenzoic acid (gallic acid) 200 mg
Crystalline cellulose - 3 mg
Lactose ---------------------------------------------- 14.8 mg
Magnesium stearate 0.2 mg < RTI ID = 0.0 >
The above components are mixed in accordance with a conventional method for producing a capsule, and filled in a gelatin capsule to prepare a capsule.
Production Example 4. Preparation of injection
Trihydroxybenzoic acid (gallic acid) 200 mg
Mannitol ------------------------------------------------ 180 mg
Sterile sterile distilled water for injection 1594 mg
Na 2 HPO 4 , 12H 2 O ----------------------------------------- 26 mg
(2 mL) per 1 ampoule in accordance with the usual injection preparation method.
Production Example 5. Production of liquid agent
Trihydroxybenzoic acid (gallic acid) 200 mg
Isolation Party ---------------------------------------------- 10 g
Mannitol ------------------------------------------------ 5 g
Purified water ------------------------------------------------
Each component was added and dissolved in purified water according to the usual liquid preparation method, and the lemon flavor was added in an appropriate amount. Then, the above components were mixed, and purified water was added thereto. The whole was added with purified water to adjust the total volume to 100 ml, And sterilized to prepare a liquid preparation.
Production Example 6. Production of Health Food
Trihydroxybenzoic acid (gallic acid) 1000 mg
Vitamin mixture -------------------------------------------
Vitamin A Acetate ------------------------------------- 70 g
Vitamin E ---------------------------------------------- 1.0 mg
Vitamin B1 --------------------------------------------- 0.13 mg
Vitamin B2 --------------------------------------------- 0.15 mg
Vitamin B6 --------------------------------------------- 0.5 mg
Vitamin B12 -------------------------------------------- 0.2 g
Vitamin C ----------------------------------------------- 10 mg
Biotin ------------------------------------------------- 10 g
Nicotinic acid amide 1.7 mg
Folic acid ------------------------------------------------- - 50 g
Calcium pantothenate ----------------------------------------- 0.5 mg
Inorganic mixture --------------------------------------------------------------------------
Ferrous sulfate ------------------------------------- 1.75 mg
Zinc oxide ---------------------------------------------- 0.82 mg
Magnesium carbonate ------------------------------------------ 25.3 mg
Potassium phosphate monohydrate 15 mg
Dicalcium phosphate ------------------------------------------- 55 mg
Potassium citrate -------------------------------------------- 90 mg
Calcium carbonate ---------------------------------------------- 100 mg
Magnesium chloride ------------------------------------------ 24.8 mg
Although the composition ratio of the above-mentioned vitamin and mineral mixture is comparatively mixed with a composition suitable for health food as a preferred embodiment, the compounding ratio may be arbitrarily modified, and the above ingredients are mixed according to a conventional method for producing healthy foods , Granules can be prepared and used in the manufacture of health food compositions according to conventional methods.
Production Example 7. Preparation of health drinks
Trihydroxybenzoic acid (gallic acid) 1000 mg
Citric acid ------------------------------------------------ 1000 mg
Oligosaccharides ---------------------------------------------- 100 g
Plum concentrate -------------------------------------------- 2 g
Taurine ------------------------------------------------ 1 g
Add purified water ---------------------------------- Total 900 mL
The above components were mixed according to a conventional health drink manufacturing method, and the mixture was stirred and heated at 85 DEG C for about 1 hour. The solution thus prepared was filtered and sterilized in a sterilized 2 L container, It is used in the production of the health beverage composition of the invention.
Claims (17)
[Chemical Formula 1]
.
Wherein said compound or a pharmaceutically acceptable salt thereof is cytotoxic in a cancer cell having resistance to an epithelial growth factor receptor (EGFR) target anticancer drug. Description: BACKGROUND OF THE INVENTION 1. Field of the Invention < RTI ID = 0.0 > A pharmaceutical composition for preventing or treating resistant cancer.
Wherein said compound or a pharmaceutically acceptable salt thereof exhibits a higher apoptosis inducing effect than a normal cancer cell in drug resistant cancer cells. The present invention provides a method for preventing or treating resistance to zotitnib or erotinib, which is a receptor tyrosine kinase target anticancer drug, A pharmaceutical composition.
The cancer may be selected from the group consisting of breast cancer, lung cancer, non-small cell lung cancer, gastric cancer, colon cancer, bone cancer, pancreatic cancer, skin cancer, head cancer, head cancer, skin cancer, malignant melanoma, uterine cancer, Hodgkin's disease, esophageal cancer, small bowel cancer, lymphadenocarcinoma, bladder cancer, gallbladder cancer, endocrine cancer, thyroid cancer, pituitary cancer, soft tissue sarcoma, soft tissue sarcoma, endometrioid carcinoma, endometrial carcinoma, endometrial carcinoma, uterine cancer, vulvar carcinoma, vulvar carcinoma, Cancer of the urethra, renal cell carcinoma, renal pelvic carcinoma, central nervous system (CNS) tumor, primary central nervous system (CNS) neoplasm, cancer of the urethra, cancer of the urethra, penile cancer, prostate cancer, chronic leukemia, acute leukemia, lymphocytic lymphoma, Lymphoma, spinal cord tumor, brainstem glioma, and pituitary adenoma. The present invention relates to a method for the prevention or treatment of resistant cancers against zetotinib or erlotinib, which are receptor tyrosine kinase target anticancer drugs For the pharmaceutical composition.
Wherein the composition is used alone or in combination with other anticancer agents. The pharmaceutical composition for preventing or treating resistance to zetitinib or erotinib, which is a receptor tyrosine kinase target anticancer agent.
[Chemical Formula 1]
.
Wherein said compound or pharmaceutically acceptable salt thereof is a receptor tyrosine kinase which is characterized by exhibiting cytotoxicity in a cancer cell having resistance to an epithelial growth factor receptor (EGFR) target anticancer drug. Cancer adjuvant for the prevention or treatment of cancer.
Wherein said compound or a pharmaceutically acceptable salt thereof exhibits a higher apoptosis inducing effect than a normal cancer cell in drug resistant cancer cells. The present invention provides a method for preventing or treating resistance to zotitnib or erotinib, which is a receptor tyrosine kinase target anticancer drug, Cancer adjuvant for.
The cancer may be selected from the group consisting of breast cancer, lung cancer, non-small cell lung cancer, gastric cancer, colon cancer, bone cancer, pancreatic cancer, skin cancer, head cancer, head cancer, skin cancer, malignant melanoma, uterine cancer, Hodgkin's disease, esophageal cancer, small bowel cancer, lymphadenocarcinoma, bladder cancer, gallbladder cancer, endocrine cancer, thyroid cancer, pituitary cancer, soft tissue sarcoma, soft tissue sarcoma, endometrioid carcinoma, endometrial carcinoma, endometrial carcinoma, uterine cancer, vulvar carcinoma, vulvar carcinoma, Cancer of the urethra, renal cell carcinoma, renal pelvic carcinoma, central nervous system (CNS) tumor, primary central nervous system (CNS) neoplasm, cancer of the urethra, cancer of the urethra, penile cancer, prostate cancer, chronic leukemia, acute leukemia, lymphocytic lymphoma, Lymphoma, spinal cord tumor, brainstem glioma, and pituitary adenoma. The present invention relates to a method for the prevention or treatment of resistant cancers against zetotinib or erlotinib, which are receptor tyrosine kinase target anticancer drugs Cancer supplements.
[Chemical Formula 1]
.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20140078148 | 2014-06-25 | ||
KR1020140078148 | 2014-06-25 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20160008105A KR20160008105A (en) | 2016-01-21 |
KR101751371B1 true KR101751371B1 (en) | 2017-06-27 |
Family
ID=54938453
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020150090436A KR101751371B1 (en) | 2014-06-25 | 2015-06-25 | Anticancer composition comprising 3,4,5-trihydroxybenzoic acid, its derivatives or its salts for preventing or treating receptor tyrosine kinase inhibitor resistant tumor |
Country Status (2)
Country | Link |
---|---|
KR (1) | KR101751371B1 (en) |
WO (1) | WO2015199454A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102181467B1 (en) * | 2018-09-14 | 2020-11-23 | 경북대학교 산학협력단 | Pharmaceutical Composition For Treating Cancer Comprising Tyrosine Kinase Inhibitor |
CN113730397A (en) * | 2020-05-27 | 2021-12-03 | 博尔诚(北京)科技有限公司 | Application of epigallocatechin gallate and/or gallic acid in inhibiting SEPT9 or BMP4 methylation |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8551554B2 (en) * | 2003-12-29 | 2013-10-08 | Cornell Research Foundation, Inc. | Apple peel powder, methods of making, and uses thereof |
KR101313702B1 (en) | 2005-02-03 | 2013-10-04 | 와이어쓰 | Pharmaceutical composition for treating gefitinib and/or erlotinib resistant cancer |
US8715665B2 (en) * | 2007-04-13 | 2014-05-06 | The General Hospital Corporation | Methods for treating cancer resistant to ErbB therapeutics |
KR101388635B1 (en) | 2012-07-25 | 2014-04-25 | 서울대학교산학협력단 | Effective anticancer drugs against gefitinib-resistant human lung cancer cells comprising the daphnane diterpenoid compound |
-
2015
- 2015-06-25 WO PCT/KR2015/006464 patent/WO2015199454A1/en active Application Filing
- 2015-06-25 KR KR1020150090436A patent/KR101751371B1/en active IP Right Grant
Non-Patent Citations (2)
Title |
---|
Gallic acid reduces cell viability, proliferation, invasion and angiogenesis in human cervical cancer cells, Oncology letters, 제6권, 제6호, 1749-1755(2013.) 1부.* |
Inhibition of human lung cancer cell proliferation and survival by wine, Cancer cell international, 제14권, 제1호, 논문번호 6, 내부페이지 1-132014 (Epub. 2014.01.23)* |
Also Published As
Publication number | Publication date |
---|---|
KR20160008105A (en) | 2016-01-21 |
WO2015199454A1 (en) | 2015-12-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2020024834A1 (en) | Combination product of bcl-2 inhibitor and chemotherapeutic agent and use thereof in the prevention and/or treatment of diseases | |
WO2020024820A1 (en) | Combination product of bcl-2 inhibitor and mdm2 inhibitor and use thereof in the prevention and/or treatment of diseases | |
RU2738934C2 (en) | Methods of treating cancer using apilimod | |
US8691870B2 (en) | Use of isothiocyanates for treating cancer | |
RU2391982C2 (en) | Antitumour agent | |
JP6090836B2 (en) | Anti-tumor activity enhancer of chemotherapeutic agent | |
US20120258181A1 (en) | Anticancer combination of artemisinin-based drugs and other chemotherapeutic agents | |
KR20140143166A (en) | Procaspase 3 activation by combination therapy | |
EP2968379A1 (en) | Etoposide and prodrugs thereof for use in targeting cancer stem cells | |
JP2015214579A (en) | Cancer cell apoptosis | |
KR101388635B1 (en) | Effective anticancer drugs against gefitinib-resistant human lung cancer cells comprising the daphnane diterpenoid compound | |
Duarte et al. | Combining repurposed drugs to treat colorectal cancer | |
KR101751371B1 (en) | Anticancer composition comprising 3,4,5-trihydroxybenzoic acid, its derivatives or its salts for preventing or treating receptor tyrosine kinase inhibitor resistant tumor | |
US20210244757A1 (en) | Pharmaceutical composition for treating cancer comprising metal ion-bound ionic compound | |
US20190231793A1 (en) | Use of harringtonines in the treatment of breast cancer, in particular triple-negative breast cancer | |
TW201311263A (en) | Wogonin-containing pharmaceutical composition for inhibiting cancer stem cells growth and application thereof | |
TWI430801B (en) | Use of berberine-containing compound for preparing drug for inhibiting cancer stem cells growth or metastasis | |
US9101631B2 (en) | Combination therapy based on SRC and aurora kinase inhibition for the treatment of cancer | |
KR20190091222A (en) | Pharmaceutical composition for use in preventing or treating cancer containing calcium channel blocker or pharmaceutically acceptable salts thereof as an active ingredient | |
CN113395968B (en) | Combination of FAK inhibitor and BTK inhibitor for the treatment of diseases | |
US20220168319A1 (en) | COMBINED USE OF A-NOR-5alpha ANDROSTANE COMPOUND DRUG AND ANTICANCER DRUG | |
WO2019176985A1 (en) | Antitumor agent, antitumor effect potentiator and antitumor kit | |
KR102639036B1 (en) | Composition for treating, alleviating or preventing brain cancer comprising berbamine and SR 140333 | |
KR102528732B1 (en) | Pharmaceutical composition for preventing or treating cancer comprising poziotinib and calcium channel blocker | |
AU2022260753B2 (en) | Anticancer composition inducing cell senescence and cell death |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant |